secwatch.observer — SEC 8-K summary
======================================

Issuer:     Cullinan Therapeutics, Inc. (CGEM)
CIK:        0001789972
Form:       8-K
Filed at:   2023-11-08T23:59:59+00:00
Accession:  0000950170-23-060673
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Cullinan Oncology reports Q3 net loss of $39.2M; cash runway extends to H2 2026
-------------------------------------------------------------------------------

- Cash and investments $481.9M at Sept 30, 2023; runway extended into H2 2026 from prior into 2026, driven by $38M ATM net proceeds and higher interest income.
- Net loss $39.2M in Q3 vs $32.2M in Q2; R&D expenses $33.8M (up from $27.4M) on higher manufacturing and clinical costs.
- CLN-619 (MICA/B) monotherapy clinical activity observed; combination dose escalation enrollment completed; initial data expected Q2 2024.
- Zipalertinib (EGFR ex20ins) Phase 2b REZILIENT1 enrollment completion targeted by end 2024; Phase 3 REZILIENT3 initiated.
- CLN-978 (CD19xCD3) first patient dosed in Phase 1 for R/R B-NHL; CLN-617 first-in-human expected by year-end 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1789972/000095017023060673/0000950170-23-060673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1789972/000095017023060673/cgem-20231108.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-060673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer